News

Tazemetostat Reduces EZH2 Activity in Patients with Malignant Mesothelioma

07/06/2022

Findings from an open-label phase 2 study reveal treatment with tazemetostat reduces EZH2 activity and B-cell infiltration in patients with relapsed or refractory, BAP1-inactivated malignant pleural mesothelioma.

Findings from an open-label...

07/06/2022

Oncology

News

Adagrasib Demonstrates Clinical Efficacy, Safety in KRAS-Mutated NSCLC

07/06/2022

Derek Cowsert ;

Findings from a phase 2 trial show promising efficacy and safety with adagrasib for patients with KRAS-mutated NSCLC.

Findings from a phase 2 trial...

07/06/2022

Oncology

News

Driver Variations Associated With Shorter PFS in Patients With NSCLC Receiving Chemoradiation and Durvalumab

07/06/2022

Derek Cowsert ;

A phase 3 cohort study identified driver variations associated with shorter PFS among patients with NSCLC receiving definitive chemoradiation and consolidative durvalumab, highlighting the need for alternative treatment options for these...

A phase 3 cohort study...

07/06/2022

Oncology

News

Tiragolumab Plus Atezolizumab Improves PFS vs Placebo Plus Atezolizumab in NSCLC: CITYSCAPE Trial

07/05/2022

Derek Cowsert ;

Tiragolumab plus atezolizumab yielded improved objective response rates and PFS vs placebo plus atezolizumab as first-line treatment for patients with NSCLC in the phase 2 CITYSCAPE trial.

Tiragolumab plus atezolizumab...

07/05/2022

Oncology

News

Selpercatinib Demonstrates Safety, Efficacy in RET-Altered NSCLC and Thyroid Cancer Regardless of Prior Treatment Status

06/28/2022

Hina M. Porcelli ;

Findings from a systematic review and meta-analysis show that selpercatinib is a safe and effective option for patients with RET-altered NSCLC and thyroid cancer, regardless of previous therapies or RET alteration type.

Findings from a systematic...

06/28/2022

Oncology

News

Selpercatinib Demonstrates Safety, Efficacy in RET-Altered NSCLC and Thyroid Cancer Regardless of Prior Treatment Status

06/28/2022

Hina M. Porcelli ;

Findings from a systematic...

06/28/2022

Oncology

News

Stereotactic Radiosurgery vs Whole Brain Radiotherapy in Patients With SCLC and Intracranial Metastatic Disease

06/16/2022

Derek Cowsert ;

Study findings reveal treatment with stereotactic radiosurgery was associated with equitable survival outcomes vs whole brain radiotherapy for intracranial metastatic disease in patients with SCLC.

Study findings reveal treatment...

06/16/2022

Oncology

News

Durvalumab With Concurrent Chemoradiotherapy Demonstrates Efficacy, Safety in SCLC

06/16/2022

Derek Cowsert ;

Study findings suggest durvalumab with concurrent chemoradiotherapy yielded promising efficacy and safety among patients with limited-stage SCLC in a phase 2 trial.

Study findings suggest...

06/16/2022

Oncology

News

Neoadjuvant Nivolumab Plus Chemotherapy Improves EFS vs Chemotherapy Alone in Resectable NSCLC

06/13/2022

Derek Cowsert ;

Neoadjuvant nivolumab plus chemotherapy prolonged EFS and yielded a higher percentage of patients with a pathological complete response vs chemotherapy alone among patients with resectable NSCLC in a phase 3 study.

Neoadjuvant nivolumab plus...

06/13/2022

Oncology

News

Pembrolizumab Associated With Survival Benefit Among Patients With NSCLC and Smoking History

06/13/2022

Derek Cowsert ;

Study findings suggest first-line pembrolizumab yielded consistently longer OS among patients with NSCLC and a history of smoking than those with no smoking history.

Study findings suggest...

06/13/2022

Oncology

Recent News

News

Intraoperative Radiation Therapy May Improve Survival For Certain Patients With Recurrent Cervical or Endometrial Cancer

11/14/2024

Allison Casey ;

According to a retrospective study, there was an appreciable survival gain for well-selected patients with recurrent or persistent endometrial or cervical cancer who receive intraoperative radiation therapy.

According to a retrospective...

11/14/2024

Oncology

News

Amrubicin Plus Irinotecan Demonstrates Promising Efficacy, Safety for Chemotherapy-Naïve Patients With Extensive-Disease Small Cell Lung Cancer

11/14/2024

Stephanie Holland ;

According to results from the phase 2 LC 08-01 trial, amrubicin plus irinotecan demonstrated promising efficacy and safety among chemotherapy-naïve patients with extensive-disease small cell lung cancer.

According to results from the...

11/14/2024

Oncology

News

Addition of Bempegaldesleukin to Nivolumab Does Not Benefit Cisplatin-Ineligible Patients With First-Line Advanced Urothelial Carcinoma

11/13/2024

Stephanie Holland ;

Results from the phase 2 PIVOT-10 trial demonstrated that the addition of bempegaldesleukin to first-line nivolumab did not improve outcomes for cisplatin-ineligible patients with locally advanced or metastatic urothelial carcinoma.

Results from the phase 2...

11/13/2024

Oncology

News

Mirdametinib for Adult and Pediatric Patients With Neurofibromatosis Type 1 With Plexiform Neurofibromas

11/12/2024

Allison Casey ;

According to a phase 2b trial, mirdametinib demonstrated significant confirmed objective response rates with deep and durable reductions of volume of target plexiform neurofibromas and clinically meaningful improvements to health-related...

According to a phase 2b trial,...

11/12/2024

Oncology

News

Epirubicin Plus Cyclophosphamide and Docetaxel Reduces Long-Term Risk of Recurrence for Patients With TOP2A Normal Early Breast Cancer

11/12/2024

Stephanie Holland ;

According to final results from the DBCG 07-READ trial, the addition of epirubicin to cyclophosphamide and docetaxel reduced long-term risk of breast cancer recurrence among patients with TOP2A normal early breast cancer.

According to final results from...

11/12/2024

Oncology

News

Pembrolizumab Plus Chemotherapy For Patients With High-Risk Endometrial Cancer

11/11/2024

Allison Casey ;

According to results from a phase 3 trial, pembrolizumab plus chemotherapy did not improve DFS among patients with high-risk endometrial cancer. However, there may be a benefit among patients with mismatch report-deficient disease.

According to results from a...

11/11/2024

Oncology

FDA Approval

FDA Grants Approval to Obecabtagene Autoleucel for R/R B-Cell Precursor Acute Lymphoblastic Leukemia

11/08/2024

On November 8, 2024, the FDA approved CD19-directed genetically modified autologous T cell immunotherapy obecabtagene autoleucel for the treatment of patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia.

On November 8, 2024, the FDA...

11/08/2024

Oncology

News

Naporafenib in Combination With Rineterkib or Tremetinib for KRAS- or BRAF-Mutant Non-Small Cell Lung Cancer

11/07/2024

Allison Casey ;

While naporafenib plus rineterkib and naporafenib plus trametinib both had acceptable safety profiles, antitumor activity was limited among patients with KRAS-/BRAF-mutant non-small cell lung cancer.

While naporafenib plus...

11/07/2024

Oncology

News

Addition of Concurrent Thoracic Radiotherapy to First-Line TKI Therapy Improves Survival for Patients With EGFR-Mutated Non-Small Cell Lung Cancer

11/06/2024

Stephanie Holland ;

According to results from a phase 3 trial, the addition of concurrent thoracic radiotherapy to first-line icotinib improved survival among patients with EGFR-mutated oligo-organ metastatic non-small cell lung cancer.

According to results from a...

11/06/2024

Oncology

News

Ipilimumab After PD-1 Inhibition Failure Among Patients With Metastatic Melanoma

11/05/2024

Allison Casey ;

A single-center real-world study found the use of ipilimumab in the second-line was an effective therapy for patients with metastatic BRAF/NRAS-wildtype metastatic melanoma without brain metastases.

A single-center real-world study...

11/05/2024

Oncology